TrialTransplantation and cellular therapy2023

Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.

Shernan G Holtan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.